Loading...

OncoMed Pharmaceuticals

DB:O0M
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
O0M
DB
$36M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence, and metastasis. The last earnings update was 45 days ago. More info.


Add to Portfolio Compare Print
  • OncoMed Pharmaceuticals has significant price volatility in the past 3 months.
O0M Share Price and Events
7 Day Returns
3.1%
DB:O0M
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-66.2%
DB:O0M
-10.2%
DE Biotechs
-6%
DE Market
O0M Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OncoMed Pharmaceuticals (O0M) 3.1% 5.6% 21.7% -66.2% -92.6% -95.6%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • O0M underperformed the Biotechs industry which returned -10.2% over the past year.
  • O0M underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
O0M
Industry
5yr Volatility vs Market
Related Companies

Value

 Is OncoMed Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for OncoMed Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €0.8236.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OncoMed Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OncoMed Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:O0M PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.21
NasdaqGS:OMED Share Price ** NasdaqGS (2019-04-18) in USD $0.94
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OncoMed Pharmaceuticals.

DB:O0M PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:OMED Share Price ÷ EPS (both in USD)

= 0.94 ÷ -0.21

-4.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OncoMed Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • OncoMed Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does OncoMed Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:O0M PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
43.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for OncoMed Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on OncoMed Pharmaceuticals's assets?
Raw Data
DB:O0M PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.25
NasdaqGS:OMED Share Price * NasdaqGS (2019-04-18) in USD $0.94
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:O0M PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:OMED Share Price ÷ Book Value per Share (both in USD)

= 0.94 ÷ 1.25

0.75x

* Primary Listing of OncoMed Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OncoMed Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess OncoMed Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. OncoMed Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is OncoMed Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
43.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OncoMed Pharmaceuticals expected to grow at an attractive rate?
  • OncoMed Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • OncoMed Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • OncoMed Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:O0M Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:O0M Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 43.6%
DB:O0M Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 29.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:O0M Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:O0M Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 195 88 1
2022-12-31 73 -14 1
2021-12-31 36 -42 1
2020-12-31 30 -19 2
2019-12-31 25 -26 1
DB:O0M Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 44 -45 -8
2018-09-30 55 -44 6
2018-06-30 40 -52 -11
2018-03-31 40 -70 -22
2017-12-31 38 -85 -39
2017-09-30 24 -95 -71
2017-06-30 25 -106 -86
2017-03-31 25 -102 -98
2016-12-31 25 -37 -103
2016-09-30 26 -32 -106
2016-06-30 25 -30 -104
2016-03-31 23 -20 -98

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • OncoMed Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • OncoMed Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:O0M Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from OncoMed Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:O0M Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.06 1.06 1.06 1.00
2022-12-31 -0.20 -0.20 -0.20 1.00
2021-12-31 -0.70 -0.70 -0.70 1.00
2020-12-31 -0.83 -0.36 -1.29 2.00
2019-12-31 -1.58 -1.58 -1.58 1.00
DB:O0M Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.21
2018-09-30 0.16
2018-06-30 -0.28
2018-03-31 -0.58
2017-12-31 -1.04
2017-09-30 -1.89
2017-06-30 -2.36
2017-03-31 -2.84
2016-12-31 -3.14
2016-09-30 -3.39
2016-06-30 -3.45
2016-03-31 -3.26

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OncoMed Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess OncoMed Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OncoMed Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has OncoMed Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OncoMed Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OncoMed Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare OncoMed Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare OncoMed Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
OncoMed Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OncoMed Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:O0M Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 44.42 -8.10 16.37
2018-09-30 54.88 6.03 16.61
2018-06-30 40.47 -10.78 16.78
2018-03-31 39.79 -22.03 17.17
2017-12-31 38.15 -39.06 16.76
2017-09-30 23.73 -70.86 17.32
2017-06-30 24.55 -86.03 17.94
2017-03-31 25.02 -98.50 18.61
2016-12-31 25.15 -103.10 18.83
2016-09-30 25.77 -105.54 19.44
2016-06-30 24.54 -104.16 19.48
2016-03-31 22.56 -98.09 18.99
2015-12-31 25.90 -85.41 18.58
2015-09-30 27.58 -75.69 17.19
2015-06-30 41.90 -56.69 16.17
2015-03-31 43.23 -50.67 15.33
2014-12-31 39.56 -50.01 13.75
2014-09-30 50.03 -39.30 14.69 -20.65
2014-06-30 43.95 -37.30 14.35 -12.89
2014-03-31 40.86 -31.34 12.86 -6.45
2013-12-31 37.78 -26.07 11.63
2013-09-30 25.73 -26.02 8.88 27.32
2013-06-30 20.54 -26.19 7.62 26.35
2013-03-31 25.10 -20.31 7.38 26.39
2012-12-31 24.68 -22.24 7.16
2012-09-30 20.36 -25.46 6.93 27.20
2012-06-30 15.24 -29.32 6.55 27.07

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if OncoMed Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if OncoMed Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if OncoMed Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess OncoMed Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OncoMed Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is OncoMed Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OncoMed Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OncoMed Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OncoMed Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of OncoMed Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • OncoMed Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OncoMed Pharmaceuticals Company Filings, last reported 3 months ago.

DB:O0M Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 48.23 0.00 57.35
2018-09-30 51.72 0.00 70.86
2018-06-30 43.98 0.00 79.87
2018-03-31 46.33 0.00 88.42
2017-12-31 -48.60 0.00 103.09
2017-09-30 -62.16 0.00 113.59
2017-06-30 -53.79 0.00 129.77
2017-03-31 -40.77 0.00 156.94
2016-12-31 -23.03 0.00 184.57
2016-09-30 -3.18 0.00 207.59
2016-06-30 -43.54 0.00 171.53
2016-03-31 -19.81 0.00 193.50
2015-12-31 3.55 0.00 157.28
2015-09-30 24.89 0.00 175.21
2015-06-30 46.31 0.00 200.23
2015-03-31 65.32 0.00 213.05
2014-12-31 76.37 0.00 231.97
2014-09-30 89.42 0.00 247.87
2014-06-30 92.30 0.00 266.35
2014-03-31 105.82 0.00 283.91
2013-12-31 118.12 0.00 316.19
2013-09-30 101.05 0.00 128.65
2013-06-30 20.82 0.00 56.46
2013-03-31 30.34 0.00 60.22
2012-12-31 38.55 0.00 66.24
2012-09-30
2012-06-30 46.04 0.14 75.79
  • OncoMed Pharmaceuticals has no debt.
  • OncoMed Pharmaceuticals had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • OncoMed Pharmaceuticals has sufficient cash runway for 1.3 years based on current free cash flow.
  • OncoMed Pharmaceuticals has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 7.7% each year.
X
Financial health checks
We assess OncoMed Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OncoMed Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is OncoMed Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OncoMed Pharmaceuticals dividends.
If you bought €2,000 of OncoMed Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OncoMed Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OncoMed Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:O0M Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:O0M Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OncoMed Pharmaceuticals has not reported any payouts.
  • Unable to verify if OncoMed Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OncoMed Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OncoMed Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OncoMed Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OncoMed Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OncoMed Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of OncoMed Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • OncoMed Pharmaceuticals has no CEO, or we have no data on them.
Management Team Tenure

Average tenure of the OncoMed Pharmaceuticals management team in years:

0.8
Average Tenure
  • The average tenure for the OncoMed Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Perry Karsen

TITLE
Executive Chairman
COMPENSATION
$744K
AGE
63
TENURE
1.3 yrs

Jill Henrich

TITLE
Senior Vice President of Regulatory Affairs & Quality Assurance
TENURE
0.8 yrs

Ann Kapoun

TITLE
Senior Vice President of Translational Medicine
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the OncoMed Pharmaceuticals board of directors in years:

5.5
Average Tenure
64
Average Age
  • The tenure for the OncoMed Pharmaceuticals board of directors is about average.
Board of Directors

Perry Karsen

TITLE
Executive Chairman
COMPENSATION
$744K
AGE
63
TENURE
1.3 yrs

Jack Lasersohn

TITLE
Director
COMPENSATION
$84K
AGE
65
TENURE
13.8 yrs

Mike Wyzga

TITLE
Independent Director
COMPENSATION
$82K
AGE
63
TENURE
5.5 yrs

Rick Winningham

TITLE
Director
COMPENSATION
$86K
AGE
58
TENURE
3.8 yrs

Jon Root

TITLE
Director
COMPENSATION
$74K
AGE
58
TENURE
14.7 yrs

Robert Zerbe

TITLE
Member of Scientific & Clinical Advisory Board
AGE
67

Roel Nusse

TITLE
Member of Scientific & Clinical Advisory Board
AGE
68

Larry Norton

TITLE
Member of Scientific & Clinical Advisory Board
AGE
71

Thomas Look

TITLE
Member of Scientific & Clinical Advisory Board

Calvin Kuo

TITLE
Member of Scientific & Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
11. Oct 18 Sell Yvonne Li Individual 10. Oct 18 10. Oct 18 -927 €1.75 €-1,624
10. Oct 18 Sell Yvonne Li Individual 09. Oct 18 09. Oct 18 -1,229 €1.85 €-2,280
15. Mar 19 Sell BVF Partners LP Company 14. Mar 19 14. Mar 19 -159,318 €0.74 €-117,705
15. Mar 19 Buy BVF Partners LP Company 14. Mar 19 14. Mar 19 159,318 €0.74 €117,705
26. Dec 18 Sell Austin Gurney Individual 24. Dec 18 24. Dec 18 -11,117 €0.53 €-5,846
11. Oct 18 Sell John Lewicki Individual 10. Oct 18 10. Oct 18 -1,156 €1.74 €-2,015
11. Oct 18 Sell Robert Stagg Individual 10. Oct 18 10. Oct 18 -927 €1.74 €-1,616
11. Oct 18 Sell Austin Gurney Individual 10. Oct 18 10. Oct 18 -1,156 €1.74 €-2,015
11. Oct 18 Sell Alicia Hager Individual 10. Oct 18 10. Oct 18 -1,156 €1.75 €-2,025
10. Oct 18 Sell John Lewicki Individual 09. Oct 18 09. Oct 18 -2,296 €1.85 €-4,259
10. Oct 18 Sell Alicia Hager Individual 09. Oct 18 09. Oct 18 -1,686 €1.85 €-3,127
10. Oct 18 Sell Robert Stagg Individual 09. Oct 18 09. Oct 18 -1,686 €1.85 €-3,127
10. Oct 18 Sell Austin Gurney Individual 09. Oct 18 09. Oct 18 -1,686 €1.85 €-3,127
26. Apr 18 Sell Yvonne Li Individual 24. Apr 18 24. Apr 18 -5,062 €2.19 €-11,092
26. Apr 18 Sell Robert Stagg Individual 24. Apr 18 24. Apr 18 -4,051 €2.19 €-8,877
26. Apr 18 Sell Alicia Hager Individual 24. Apr 18 24. Apr 18 -4,051 €2.19 €-8,877
26. Apr 18 Sell John Lewicki Individual 24. Apr 18 24. Apr 18 -4,557 €2.19 €-9,985
26. Apr 18 Sell Austin Gurney Individual 24. Apr 18 24. Apr 18 -4,051 €2.19 €-8,877
X
Management checks
We assess OncoMed Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OncoMed Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.

Details
Name: OncoMed Pharmaceuticals, Inc.
O0M
Exchange: DB
Founded: 2004
$32,335,593
38,690,089
Website: http://www.oncomed.com
Address: OncoMed Pharmaceuticals, Inc.
800 Chesapeake Drive,
Redwood City,
California, 94063,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS OMED Common Stock Nasdaq Global Select US USD 18. Jul 2013
DB O0M Common Stock Deutsche Boerse AG DE EUR 18. Jul 2013
Number of employees
Current staff
Staff numbers
22
OncoMed Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:34
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/08
Last earnings filing: 2019/03/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.